Nurix Therapeutics, Inc. Stock News

SAN FRANCISCO, March 06, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pat

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -27.94% and 65.46%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the

SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pati

Nurix Therapeutics, Inc. (NRIX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analy

Webcast Scheduled for Monday, December 12, 2022 at 8:30 PM CT (9:30 PM ET) Webcast Scheduled for Monday, December 12, 2022 at 8:30 PM CT (9:30 PM ET)

The consensus price target hints at an 187% upside potential for Nurix Therapeutics, Inc. (NRIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e

SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hemat

There are four key data catalysts, one in each of Nurix's clinical candidates, arriving through end of the year. Nurix has a strong cash position that should be sufficient to fund operations through 2

It has been another volatile week for Cathie Wood's flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEARCA: ARKK ). Shares of ARKK recently hit a five-year low and 52-week low of $33.74

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 9.09% and 12.33%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stoc

Nurix Therapeutics, Inc. (NRIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

SAN FRANCISCO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sa

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -1% and 13.36%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?

Nurix Therapeutics, Inc. (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in t

SAN FRANCISCO, May 11, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.  (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced th